tiprankstipranks
NKGen Biotech (NKGN)
OTHER OTC:NKGN
US Market
NKGN
NKGen Biotech
RESEARCH TOOLSreports
Want to see NKGN full AI Analyst Report?

NKGen Biotech (NKGN) Ratios

121 Followers

NKGen Biotech Ratios

NKGN's free cash flow for Q1 2025 was $0.00. For the 2025 fiscal year, NKGN's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
 0.05 0.00 0.05 0.02
Quick Ratio
 0.05 0.00 0.05 0.02
Cash Ratio
 <0.01 0.00 <0.01 <0.01
Solvency Ratio
 -0.22 0.00 -1.09 -1.73
Operating Cash Flow Ratio
 -0.22 0.00 -0.56 -1.53
Short-Term Operating Cash Flow Coverage
 -0.36 0.00 -2.20 -1.94
Net Current Asset Value
$ -63.79M$ 24.00K$ -73.24M$ -14.42M
Leverage Ratios
Debt-to-Assets Ratio
 2.41 0.00 1.21 0.74
Debt-to-Equity Ratio
 -0.76 0.00 -0.34 7.70
Debt-to-Capital Ratio
 -3.15 0.00 -0.51 0.89
Long-Term Debt-to-Capital Ratio
 -0.28 0.00 -0.20 0.00
Financial Leverage Ratio
 -0.31 0.00 -0.28 10.45
Debt Service Coverage Ratio
 0.03 -9.92 -7.55 -1.66
Interest Coverage Ratio
 -1.80 -9.90 -39.93 -10.56
Debt to Market Cap
 4.83 0.00 0.47 0.10
Interest Debt Per Share
 1.51 0.09 1.34 0.67
Net Debt to EBITDA
 39.29 0.00 -0.25 -0.51
Profitability Margins
Gross Profit Margin
50.00%0.00%0.00%76.62%
EBIT Margin
4377.76%0.00%0.00%-31741.56%
EBITDA Margin
149.08%0.00%0.00%-30170.13%
Operating Profit Margin
-1497.85%0.00%0.00%-31618.18%
Pretax Profit Margin
-2148.93%0.00%0.00%-34736.36%
Net Profit Margin
-2157.06%0.00%0.00%-34745.45%
Continuous Operations Profit Margin
-2157.06%0.00%0.00%-34745.45%
Net Income Per EBT
100.38%100.12%100.01%100.03%
EBT Per EBIT
143.47%164.03%278.85%109.86%
Return on Assets (ROA)
-88.78%-184525.00%-503.33%-163.83%
Return on Equity (ROE)
55.88%0.00%141.34%-1711.71%
Return on Capital Employed (ROCE)
34.82%-112358.33%129.49%-1532.16%
Return on Invested Capital (ROIC)
859.68%-112358.33%229.17%-178.71%
Return on Tangible Assets
-89.32%-184525.00%-506.16%-164.81%
Earnings Yield
-813.03%-234.45%-195.54%-21.84%
Efficiency Ratios
Receivables Turnover
 28.35 0.00 0.00 0.80
Payables Turnover
 0.02 0.00 0.00 0.02
Inventory Turnover
 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.05 0.00 0.00 <0.01
Asset Turnover
 0.04 0.00 0.00 <0.01
Working Capital Turnover Ratio
 -0.03 0.00 0.00 >-0.01
Cash Conversion Cycle
 -17.05K 0.00 0.00 -19.32K
Days of Sales Outstanding
 12.88 0.00 0.00 455.06
Days of Inventory Outstanding
 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 17.06K 0.00 0.00 19.77K
Operating Cycle
 12.88 0.00 0.00 455.06
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.34 -0.72 -1.42 -1.05
Free Cash Flow Per Share
 -0.34 -0.72 -1.43 -1.06
CapEx Per Share
 <0.01 0.00 <0.01 <0.01
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.01
Dividend Paid and CapEx Coverage Ratio
 -278.66 0.00 -457.25 -138.39
Capital Expenditure Coverage Ratio
 -278.66 0.00 -457.25 -138.39
Operating Cash Flow Coverage Ratio
 -0.26 0.00 -1.10 -1.87
Operating Cash Flow to Sales Ratio
 -14.96 0.00 0.00 -292.95
Free Cash Flow Yield
-124.91%-110.54%-51.85%-18.55%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -0.12 -0.43 -0.51 -4.58
Price-to-Sales (P/S) Ratio
 12.02 0.00 0.00 1.59K
Price-to-Book (P/B) Ratio
 -0.03 0.00 -0.72 78.37
Price-to-Free Cash Flow (P/FCF) Ratio
 -0.80 -0.90 -1.93 -5.39
Price-to-Operating Cash Flow Ratio
 -0.18 -0.90 -1.93 -5.43
Price-to-Earnings Growth (PEG) Ratio
 >-0.01 <0.01 >-0.01 -0.29
Price-to-Fair Value
 -0.03 0.00 -0.72 78.37
Enterprise Value Multiple
 47.35 -0.70 -0.77 -5.79
Enterprise Value
 46.02M 18.89M 62.32M 134.41M
EV to EBITDA
 47.35 -0.70 -0.77 -5.79
EV to Sales
 70.59 0.00 0.00 1.75K
EV to Free Cash Flow
 -4.70 -0.90 -2.83 -5.92
EV to Operating Cash Flow
 -4.72 -0.90 -2.84 -5.96
Tangible Book Value Per Share
 -1.75 <0.01 -3.81 0.07
Shareholders’ Equity Per Share
 -1.75 0.00 -3.80 0.07
Tax and Other Ratios
Effective Tax Rate
 >-0.01 >-0.01 >-0.01 >-0.01
Revenue Per Share
 0.02 0.00 0.00 <0.01
Net Income Per Share
 -0.49 -1.54 -5.38 -1.25
Tax Burden
 1.00 1.00 1.00 1.00
Interest Burden
 -0.49 1.07 1.01 1.09
Research & Development to Revenue
 5.69 0.00 0.00 217.48
SG&A to Revenue
 9.79 0.00 0.00 99.47
Stock-Based Compensation to Revenue
 2.37 0.00 0.00 0.90
Income Quality
 0.69 0.47 0.26 0.84
Currency in USD